Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132

Benzinga · 2d ago
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $136 to $132.